Compare Mesoblast Limited (MESO) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs OneSpan Inc — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while OneSpan Inc trades at $15.31 (market cap $575.37M). The key difference: Mesoblast Limited is far larger — about 3.8× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OSPN | |
|---|---|---|
Market Cap | $2.17B | $575.37M |
Sector | Technology | Technology |
52-Week High | $20.96 | $16.32 |
52-Week Low | $12.88 | $10.15 |
Enterprise Value | $2.17B | $533.57M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
OneSpan (OSPN) trades at $15.51, showing modest daily gains of 0.26% with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with a 28.47% net income margin and consistent earnings beats in recent quarters. Recent corporate developments include a $0.13 dividend payment and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents attractive valuation metrics with a P/E of 8.55 and strong analyst support (66.7% buy ratings), though current price exceeds the $13.50 consensus target. Key risks include negative cash flow trends and competitive pressures in the cybersecurity sector. Earnings growth remains the primary catalyst for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
